The Clinical Oncology Specialist will serve as a strategic field partner and key representative of Natera Oncology, developing relationships with Key Opinion Leaders (KOLs) and healthcare providers across academic medical centers, integrated delivery networks, hospital systems, and select community oncology practices. Across GU cancers, including bladder, renal cell carcinoma, and testicular cancers, Signatera provides highly specific molecular insights that can help clinicians assess recurrence risk, monitor disease status, and inform individualized patient management strategies.